Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

10.79 +1.30 (+13.70%)

Streaming Delayed Price Updated: 12:33 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	6,020,391
Open	9.820
Bid (Size)	10.77 (200)
Ask (Size)	10.79 (400)
Prev. Close	9.490
Today's Range	9.760 - 10.94
52wk Range	4.155 - 10.29
Shares Outstanding	133,976,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vir Biotechnology Announces Proposed Public Offering of Common Stock

February 24, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Tuesday's session: top gainers and losers ↗

February 24, 2026

Via Chartmill

Performance

YTD	+81.6%	+81.6%
1 Month	+44.8%	+44.8%
3 Month	+67.5%	+67.5%
6 Month	+143.0%	+143.0%
1 Year	+13.9%	+13.9%

More News

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

February 24, 2026

Via Chartmill

Which stocks are moving before the opening bell on Tuesday? ↗

February 24, 2026

Via Chartmill

Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗

February 23, 2026

Via Chartmill

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Via Stocktwits

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗

February 23, 2026

Via Stocktwits

Vir Biotechnology (VIR) Earnings Call Transcript ↗

February 23, 2026

Via The Motley Fool

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

February 09, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 12, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

December 16, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Via The Motley Fool

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

November 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

November 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 05, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

November 03, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

October 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

October 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

October 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?

Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.

What exchange does Vir Biotechnology, Inc. - Common Stock trade on?

Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?

The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market

What is the current price of Vir Biotechnology, Inc. - Common Stock?

The current price of Vir Biotechnology, Inc. - Common Stock is 10.79

When was Vir Biotechnology, Inc. - Common Stock last traded?

The last trade of Vir Biotechnology, Inc. - Common Stock was at 02/25/26 12:33 PM ET

What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?

The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.45B

How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?

Vir Biotechnology, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.